Aurora Cannabis Refutes Curaleaf Claims in Hostile Takeover Defense
Aurora Cannabis (ACB) publicly disputed statements made by Curaleaf Holdings in support of its unsolicited acquisition proposal.
Close-up of two professionals shaking hands in an office, symbolizing successful business dealings.
Aurora Disputes Curaleaf's Valuation and Strategic Claims
Aurora Cannabis publicly corrected multiple statements Curaleaf made to shareholders and the market in defense materials supporting the unsolicited offer. The company didn't disclose the specific dollar figures or valuation metrics disputed, but characterized the corrections as material to investor decision-making. Aurora's board has recommended shareholders reject Curaleaf's all-stock proposal, which was launched earlier this month without prior negotiation.
The rebuttal marks an escalation. Curaleaf (CURA) has framed the combination as a path to cross-border scale and improved margins, while Aurora has maintained that the offer undervalues its medical cannabis franchise and international distribution network.
Financial Position and EBITDA Trajectory at Center of Dispute
Aurora specifically challenged Curaleaf's characterization of Aurora's adjusted EBITDA performance and cash runway. In its most recent quarterly filing, Aurora reported CA$12.3 million in adjusted EBITDA for the quarter ended June 30, 2026, and CA$47.8 million in cash and short-term investments. The company has guided to positive free cash flow by fiscal Q4 2027.
Curaleaf's offer materials reportedly cited Aurora's need for capital as a rationale for the transaction. Aurora's correction filing pushed back on that framing, pointing to sequential EBITDA improvement and cost reductions executed over the past four quarters—though the company didn't provide updated guidance, it reiterated its fiscal 2027 profitability target.
Board Independence and Shareholder Communication Strategy
Aurora also addressed statements about its board composition and the process by which it evaluated Curaleaf's proposal. The company emphasized that its special committee of independent directors unanimously determined the offer wasn't in the best interests of shareholders after reviewing the proposal with financial and legal advisors. Aurora retained Stifel GMP as its financial advisor and Stikeman Elliott LLP as legal counsel.
Curaleaf hasn't yet filed a formal takeover circular with Canadian securities regulators. Under Canadian takeover rules, Curaleaf must mail its offer to Aurora shareholders within 105 days of the initial announcement. Aurora's corrections are likely intended to frame the narrative ahead of that mailing.
What Happens Next in the Hostile Bid Timeline
The next milestone is Curaleaf's formal offer document, expected by late September 2026. Aurora shareholders will then have a minimum 35-day window to tender their shares. If Curaleaf fails to secure more than 50% acceptance, the offer lapses. If it crosses that threshold, a second-stage compulsory acquisition could follow under Canadian corporate law.
Aurora hasn't ruled out soliciting alternative bids or executing a defensive transaction, though no white knight has emerged publicly. The company's stock closed at CA$4.12 on August 23, down 18% year-to-date. Curaleaf's shares have declined 22% over the same period. For full background on this story, see the CannIntel topic hub on the Curaleaf-Aurora hostile takeover.
Frequently asked questions
What did Aurora Cannabis dispute in Curaleaf's takeover materials?
Aurora disputed Curaleaf's characterization of Aurora's adjusted EBITDA performance, cash runway, and the board's evaluation process. The company called the statements materially inaccurate but didn't disclose specific dollar figures contested.
When will Curaleaf mail its formal takeover offer to Aurora shareholders?
Curaleaf must mail its formal offer circular within 105 days of the initial announcement. The document is expected by late September 2026, after which shareholders will have at least 35 days to tender their shares.
What is Aurora's current financial position?
Aurora reported CA$12.3 million in adjusted EBITDA for Q1 fiscal 2027 and CA$47.8 million in cash and short-term investments as of June 30, 2026. The company has guided to positive free cash flow by fiscal Q4 2027.
Can Aurora block Curaleaf's hostile takeover bid?
Aurora's board can recommend rejection, but the final decision rests with shareholders. If fewer than 50% of shares are tendered, the offer lapses. Aurora could also solicit alternative bids or execute a defensive transaction.
Who is advising Aurora in the hostile takeover defense?
Aurora retained Stifel GMP as its financial advisor and Stikeman Elliott LLP as legal counsel. A special committee of independent directors evaluated the proposal and unanimously recommended rejection.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business
Baby Boomers Drive $500M Cannabis Market Across Michigan, Ohio
Consumers aged 60+ now account for half a billion dollars in annual sales across the two Midwest adult-use states.
Springfield Cannabis Workers Ratify Missouri's Second Union Contract
Four-year organizing effort ends with ratification at Springfield dispensary, marking rare labor win in state's cannabis sector.
Illinois THC Beverage Ban Threatens Lifeline for Local Breweries
State regulators may shut down hemp-derived THC drinks by year's end, jeopardizing revenue stream that rescued struggling craft brewers.
More from the newsroom
California Lawmakers Approve Bill Restricting Child-Attractive Cannabis Packaging
The legislation bans cannabis product packaging designed to appeal to minors, moving to the governor's desk.
Massachusetts Voters Back Psychedelics Ballot Measure in August Poll
A new survey shows majority support for the state's November psychedelics legalization question, with cannabis-related measures also polling favorably.
Daily Marijuana Use Surpasses Alcohol and Cigarettes, Federal Data Shows
Cannabis overtakes traditional substances in daily-use prevalence for the first time in U.S. tracking history.